| |
Nano Group |
Ferro Group |
Stenting Control |
ANOVA, p value |
| |
n=60 |
n=60 |
n=60 |
|
| Subset |
Stent proximal |
Pre-dilatation with balloon |
No preparation |
Stent proximal |
Pre-dilatation with balloon |
No preparation |
| No. patients |
n=6
(10.0%) |
n=9
(15.0%) |
n=45
(75.0%) |
n=7
(11.7%) |
n=11
(18.3%) |
n=42
(70.0%) |
| Age, yr |
52.1 ± 9.4 (95% CI: 54,37-62) |
50.9 ± 9.7 (95% CI: 52, 38-63) |
51.3 ± 10.5 (95% CI: 53, 36-64) |
55.2 ± 9.2 (95% CI: 54, 37-61) |
53.3 ± 7.9 (95% CI: 54, 39-59) |
52.8 ± 9.1 (95% CI: 54, 38-61) |
52.6 ± 6.8 (95% CI: 51,49-60) |
NS |
| Males, no. of patients (%) |
2 (33.3%) |
2 (22.2%) |
41 (91.1%) |
1 (14.3%) |
4 (36.4%) |
39 (92.9%) |
46 (76.7%) |
<0.05 |
| Body-mass index |
29.1 ± 4.7 (95% CI: 28.8, 24.2-32.7) |
29.4 ± 5.3 (95% CI: 30.3, 26.5-35.3) |
30.5 ± 4.9 (95% CI: 31.0, 26.5-34.8) |
28.2 ± 4.8 (95% CI: 29.7, 24.8-33.1) |
26.4 ± 7.2 (95% CI: 28.2, 23.8-34.1) |
27.6 ± 5.4 (95% CI: 28.2, 24.3-32.7) |
27.8 ± 6.2 (95% CI: 29.1, 24.3-33.8) |
NS |
Smoking, no. (%)
• Never
• Stopped
• Current
|
1 (16.7%)
1 (16.7%)
4 (66.7%) |
2 (22.2%)
1 (11.1%)
6 (66.7%) |
6 (13.3%)
3 (6.7%)
36 (80.0%) |
2 (28.6%)
1 (14.3%)
4 (57.1%) |
2 (18.2%)
3 (27.3%)
6 (54.5%) |
7 (16.7%)
6 (14.3%)
27 (64.3%) |
7 (11.7%)
11 (18.3%)
42 (70.0%) |
NS
0.05
NS |
| Alcohol abusers, no. (%) |
4 (66.7%) |
5 (55.6%) |
20 (44.4%) |
5 (71.4%) |
7 (63.6%) |
25 (59.5%) |
25 (41.7%) |
<0.05 |
| Diabetes, no. (%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
NS |
| Hypertension needing drugs, no. (%) |
6 (100%) |
9 (100%) |
37 (61.7%) |
7 (100%) |
11 (100%) |
31 (73.8%) |
54 (90.0%) |
<0.05 |
| Treated hypertension, no. (%) |
5 (83.3%) |
7 (77.8%) |
32 (71.1%) |
6 (85.7%) |
9 (81.8%) |
29 (69.0%) |
45 (75.0%) |
NS |
| Hyperlipidemia needing drugs, no. (%) |
6 (100%) |
9 (100%) |
38 (84.4%) |
6 (85.7%) |
10 (90.9%) |
35 (83.3%) |
52 (86.7%) |
NS |
| Treated hyperlipidemia, no. (%) |
5 (83.3%) |
8 (88.9%) |
31 (68.9%) |
6 (85.7%) |
8 (72.7%) |
28 (66.7%) |
43 (71.7%) |
NS |
| Previous or simultaneous target vessel intervention, no. (%) |
6 (100%) |
2 (22.2%) |
0 (0%) |
7 (100%) |
0 (0%) |
0 (0%) |
10 (16.7%) |
0.05 |
| Previous myocardial infarction, no. (%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
NS |
CAD, no. (%)
• Single-vessel disease
• Two-vessel disease
• Three-vessel disease
|
1 (16.7%)
1 (16.7%)
4 (66.7%) |
1 (11.1%)
6 (66.7%)
2 (22.2%) |
13(28.9%)
32(71.1%)
0 (0%) |
0 (0.0%)
3 (42.9%)
4 (57.1%) |
2 (18.2%)
4 (36.4%)
5 (45.5%) |
17 (40.5%)
25 (59.5%)
0 (0%) |
19 (31.7%)
32 (53.3%)
9 (15.0%) |
NS
NS
<0.05 |
Stable angina, no. (%)
• CCS Class I
• CCS Class II
• CCS Class III
|
6 (100%)
3(50.0%)
3 (50.0%)
0 (0%) |
9 (100%)
4 (44.4%)
5 (55.6%)
0 (0%) |
44 (97.8%)
21 (46.7%)
23 (51.1%)
0 (0%) |
7 (100%)
4 (57.1%)
3 (42.9%)
0 (0%) |
11 (100%)
4 (36.4%)
7 (63.6%)
0 (0%) |
42 (100%)
22 (52.4%)
20 (47.6%)
0 (0%) |
59 (98.3%)
22 (36.7%)
37 (61.7%)
0 (0%) |
NS
NS
NS
NS |
| Unstable angina, no. (%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
NS |
| Silent ischemia, no. (%) |
1 (16.7%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
1 (1.7%) |
NS |
NYHA functional class of heart failure, no. (%)
• Class I
• Class II
• Class III
• Class IV
|
0 (0%)
3 (50.0%)
3 (50.0%)
0 (0%) |
0 (0%)
7 (77.8%)
2 (22.2%)
0 (0%) |
0 (0%)
19 (43.2%)
25 (56.8%)
0 (0%) |
0 (0%)
2 (28.6%)
5 (71.4%)
0 (0%) |
0 (0%)
6 (54.5%)
5 (45.5%)
0 (0%) |
0 (0%)
26 (61.9%)
16 (38.1%)
0 (0%) |
0 (0%)
41 (68.3%)
19 (31.7%)
0 (0%) |
NS
<0.05
<0.05
NS |
| ASS, no. (%) |
6 (100%) |
9 (100%) |
44 (97.8%) |
7 (100%) |
11 (100%) |
42 (100%) |
60 (100%) |
NS |
| Clopidogrel, no. (%) |
6 (100%) |
9 (100%) |
34 (77.3%) |
7 (100%) |
11 (100%) |
34 (80.9%) |
59 (98.3%) |
NS |
Target vessel, no. (%)
• Left anterior descending
• Left circumflex
• Right coronary artery
|
4 (66.7%)
1 (16.7%)
1 (16.7%) |
8 (88.9%)
1 (23.3%)
0 (0%) |
23 (51.1%)
12 (26.7%)
10 (22.2%) |
6 (85.7%)
1 (14.3%)
0 (30.0%) |
9 (81.8%)
1 (9.1%)
1 (9.1%) |
17 (40.5%)
8 (19.0%)
17 (40.5%) |
29 (48.3%)
13 (21.7%)
18 (30.0%) |
NS
NS
<0.05 |
AHA/ ACC lesion classification, no. (%)
• A
• B1
• B2
• C
|
0 (0%)
4 (66.7%)
2 (33.3%)
0 (0%) |
0 (0%)
3 (33.3%)
6 (66.7%)
0 (0%) |
3 (6.7%)
22 (48.9%)
18 (40.0%)
2 (4.4%) |
0 (0%)
2 (56.7%)
5 (35.0%)
0 (0%) |
0 (0%)
4 (56.7%)
7 (35.0%)
0 (0%) |
4(9.5%)
28 (66.7%)
9 (21.4%)
1 (2.4%) |
4 (6.7%)
31 (51.7%)
23 (38.3%)
2 (3.3%) |
NS
NS
<0.05
NS |
| Pre-procedure SYNTAX score, <22 only |
18.6 ± 4.6 (95% CI: 19.0, 13.5-21.5) |
18.9 ± 6.4 (95% CI: 19.5, 12.0-21.5) |
17.5 ± 5.7 (95% CI: 18.2, 15.8-21.5) |
15.8 ± 4.3 (95% CI: 16.0, 11.5-21.5) |
16.1 ± 5.3 (95% CI: 15.9, 11.2-21.5) |
16.5 ± 6.5 (95% CI: 17.8, 10.0-21.5) |
15.4 ± 4.5 (95% CI: 15.2, 8.5-21.5) |
NS |
Data are mean (SD) or number (%). CCS=Canadian Cardiovascular Society classification of angina pectoris. AHA/ACC=American Heart Association/ American College of
Cardiology. Difference between groups and subsets is non-significant. Continuous variables are expressed as mean ± SD (95%CI: median, min-max), where SD – standard
deviation, CI – confidentiality interval.NS – non-significant (p>0.05)